Hello, Thanks for signing up for MarketBeat Daily Ratings—we’re excited to have you on board. Every weekday, you’ll get a curated summary of new “Buy” and “Sell” ratings from Wall Street’s top-rated analysts, the latest stock news, and bonus investing content—all delivered straight to your inbox. You’re just two quick steps away from completing your sign-up: 1. Make sure our emails go to your inbox Gmail users:
Mobile: Tap the three dots (…) in the top right and select Move to Inbox or Move to Primary
Desktop: Click the folder icon at the top and select Move to Inbox or Primary Apple Mail users:
Tap our email address at the top (next to From: on mobile), then select Add to VIP Other providers:
Reply to this message and add newsletters@analystratings.net to your contacts 2. Confirm your subscription Click this link to confirm your subscription. This verifies your account and ensures you receive your newsletters without interruption instead of getting stuck in your spam filter. Confirm your subscription here. After you confirm, feel free to download our popular free report, "7 Stocks to Buy and Hold Forever" with this link. Thanks again for subscribing—we look forward to being part of your investing journey. 
Matthew Paulson
Founder and CEO, MarketBeat. P.S. If you didn’t mean to subscribe, no problem—you can unsubscribe here.
This Month's Featured News 3 Companies at the Forefront of the GLP-1 Pill WarsAuthored by Nathan Reiff. Publication Date: 3/16/2026. 
Key Points - Three companies to watch in the fast-growing GLP-1 space include firms with market capitalizations ranging from about $4 billion to nearly $1 trillion.
- Eli Lilly's size and dominant position allow it to develop multiple GLP-1 medicines and to expand rapidly into many corners of the world.
- Viking Therapeutics and Structure Therapeutics are much smaller, but each has a highly promising GLP-1 candidate working its way through the clinical trial process.
- Special Report: Elon Musk's $1 Quadrillion AI IPO
Though the first GLP-1 agonists date back more than 20 years, they've only recently begun to dominate the pharmaceutical space because of their potential as weight-loss treatments. With some estimates placing the market at nearly $63 billion in early 2026, forecasts call for the GLP-1 industry to roughly triple over the coming decade. It's no surprise the biopharma industry is racing to capture a share of that growth as GLP-1 use accelerates. Dozens of new GLP-1 receptor agonists are in development across nearly as many firms—and it's not just the big pharma names getting involved. The medicine is evolving quickly, expanding to include oral treatments, including the FDA's first-ever approval of a GLP-1 pill for weight loss—Wegovy—at the end of 2025. Amid the significant turbulence and hype surrounding this fast-growing space, the companies below may be particularly interesting to watch. Multiple Products and Geographies Could Cement Eli Lilly's Dominance I've worked for the CIA, personally met four US presidents, and spent 45 years studying the markets—calling Black Monday six weeks before it happened, predicting the fall of the Berlin Wall, and pinpointing the exact bottom in 2009. But what I'm about to share with you is the boldest prediction of my career. After meeting Elon Musk face-to-face at a private gathering of Wall Street elites and months of my own research, I'm now staking my reputation on one date: March 26, 2026. That's when I believe Elon will announce the SpaceX IPO—what Bloomberg is calling the biggest listing of all time. I have found an access code that lets you grab a pre-IPO stake before it happens, but in 72 hours, your window could close. Click here to see how to claim your SpaceX access code Eli Lilly and Company (NYSE: LLY) is one of the world's largest pharmaceutical companies, with a market capitalization approaching $1 trillion after shares climbed by almost 20% in the last year. This scale plays to Eli Lilly's advantage as it expands its GLP-1 program globally. The company plans to spend $3 billion in China over the coming decade to expand its supply chain and build local manufacturing capacity, including for GLP-1 medications. That investment would both enhance access to China's growing weight-loss market and help shore up global supply. Also in China, Eli Lilly recently filed for approval of a new GLP-1 treatment and completed a Phase 1 trial for a related medication. Last quarter, the company submitted orforglipron, a new GLP-1 agonist, for obesity treatment in the United States and more than three dozen additional countries, with an expected domestic launch by mid-2026. Lilly's sizable R&D budget has also allowed it to advance retatrutide, a so-called "triple-agonist" that combines GLP-1 activity with other mechanisms and is currently in clinical trials. Eli Lilly is positioning itself to dominate the GLP-1 space with multiple products—including pill-form options—launched around the world. With 45% year-over-year (YOY) revenue growth in 2025, this push could help sustain rapid top-line gains going forward. Viking's Dual Agonist Drug Shows Potential As It Moves Through Trial Process A much smaller firm than Eli Lilly, Viking Therapeutics Inc. (NASDAQ: VKTX) has not yet brought a GLP-1 drug to market. Its candidate, VK2735—a dual agonist of GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptors—has been advancing through clinical trials. In January 2025, the company reported Phase 2 results showing promise, including weight losses of nearly 15% of baseline body weight in participants and no clear plateau. Viking is developing VK2735 in both oral and injectable forms and expects to begin Phase 3 trials for the oral formulation in the coming months. To date, the drug's prospects have helped VKTX shares rise by nearly 20% over the past 12 months. However, investors may worry the company will struggle to bring the drug to market quickly enough to capture a meaningful share, given the many alternatives already available or advancing through development. The company is not currently profitable, although as of the latest quarter it held about $706 million in cash reserves. Structure's GLP-1 Pill Could Be Big, But Trial Results Will Confirm Shares of Structure Therapeutics (NASDAQ: GPCR) have outperformed both companies above over the past year, rising by more than 150% as investors grew enthusiastic about aleniglipron, the firm's GLP-1 agonist candidate. Analysts still see significant upside: consensus forecasts put GPCR's potential at over 90% upside based on a price target of $107.90. Compelling results from the Phase 2B trial made headlines in December 2025, and investors are now waiting for additional data. If upcoming results confirm aleniglipron's promise, investors who take a chance on GPCR shares could be rewarded. As with any early-stage biotech, though, the outcome remains uncertain and carries significant risk. | 
Post a Comment
Post a Comment